Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.64 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780388 | 0.91 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL10452716 | 0.91 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL809482 | 0.91 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL12639368 | 0.88 | VCAM1 (0.65) | VCAM1KIF18ANPBWR1MCHR1ALDH1A1 | |
| SCHEMBL10719874 | 0.87 | VCAM1 (0.63) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL28674925 | 0.87 | KIF18A (0.59) | VCAM1KIF18AKMT2AMEN1RAB9A | |
| SCHEMBL11044862 | 0.86 | KMT2A (0.73) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL4617709 | 0.85 | VCAM1 (0.61) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL11047958 | 0.85 | VCAM1 (0.65) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL11052823 | 0.82 | VCAM1 (0.66) | VCAM1NPBWR1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103052671-A | Novel polymer, method for producing same, and film | JSR CORP | 2013-04-17 | — | — | CN | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2008060999-A1 | PIPERIDINYL ARYLSULFONE DERIVATIVES AS MODULATORS OF SECRETED FRIZZLED RELATED PROTEIN-1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
| EP-0617010-B1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| US-5900432-A | Therapeutic N-(4-benzoyl-2-methyl-phenyl)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanamides | ZENECA LIMITED (GB) | 1999-05-04 | — | — | US | disclosed |
| EP-0625511-B1 | Heterocyclic compounds and their use in pharmaceutical | ZENECA LTD (GB) | 1999-02-17 | — | — | EP | disclosed |
| US-5700798-A | Methods for using benzoxazines for treating asthma | ZENECA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0698022-B1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5504089-A | TREATING URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1996-04-02 | — | — | US | disclosed |
| EP-0698022-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5486515-A | 2-fluoroalkyl-1,4-benzoxaxines as potassium channel mediators | ZENECA LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| US-5482969-A | Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide derivatives | ZENECA LIMITED (GB) | 1996-01-09 | — | — | US | disclosed |
| WO-1994026739-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0625511-A1 | Heterocyclic compounds and their use in pharmaceutical | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| EP-0617010-A1 | Therapeutic compounds | ZENECA LIMITED (GB) | 1994-09-28 | — | — | EP | disclosed |
| US-4808723-A | Process for the preparation of benzothiazoles | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | VCAM1 2183/4885KIF18A 4175/4885NPBWR1 1379/4885 |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | VCAM1 293/4885KIF18A 2892/4885NPBWR1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.